MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-04-2026
Ocugen P/E Ratio 2011-2026 | OCGN
Annual P/E Ratio Ocugen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.07 | -3.07 | -6.47 | -2.5 | -11.8 | -9.1 | -0.367 | -0.581 | -2.42 | -1.38 | -1.24 | -0.569 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.367 | -11.8 | -4.04 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
-1.71 | - | - | $ 26.5 M |  USA |
 |
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M |  Germany |
 |
Allakos
ALLK
|
-0.612 | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-66.5 | $ 4.65 | 1.5 % | $ 11.2 B |  Australia |
 |
Akouos
AKUS
|
-1.98 | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
-0.189 | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-0.077 | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-4.91 | $ 0.88 | - | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
14.1 | $ 22.56 | -0.49 % | $ 3.74 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-0.175 | - | - | $ 10.1 M | USA |
 |
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Applied Therapeutics
APLT
|
-4.52 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-0.146 | - | -39.0 % | $ 4.57 M | USA |
 |
Avenue Therapeutics
ATXI
|
-0.0467 | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
-4.94 | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
-0.203 | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-0.791 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-0.136 | - | 17.91 % | $ 11.1 M | USA |
 |
Atreca
BCEL
|
-0.504 | - | -11.76 % | $ 5.79 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-0.544 | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
6.11 | $ 101.7 | -0.35 % | $ 27.2 B | Germany |
 |
BioDelivery Sciences International
BDSI
|
3.63 | - | -4.8 % | $ 255 M | USA |
 |
Aquestive Therapeutics
AQST
|
-5.58 | $ 4.1 | 0.12 % | $ 438 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-213 | $ 23.01 | -1.2 % | $ 2.93 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.12 | $ 1.43 | -3.38 % | $ 381 M | Britain |
 |
Aptose Biosciences
APTO
|
-0.0913 | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
706 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
4.63 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.489 | $ 2.99 | 2.75 % | $ 4.92 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
-392 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | USA |
 |
Evogene Ltd.
EVGN
|
-2.18 | $ 0.8 | 1.25 % | $ 27.9 M | Israel |
 |
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | Germany |
 |
bluebird bio
BLUE
|
-0.316 | - | - | $ 546 M | USA |
 |
Cara Therapeutics
CARA
|
-0.457 | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-29.7 | - | - | $ 35.4 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-0.22 | $ 1.04 | -1.56 % | $ 12.7 M | USA |
 |
ChemoCentryx
CCXI
|
-0.0138 | - | - | $ 3.74 B | USA |
 |
Cabaletta Bio
CABA
|
-1.69 | $ 2.82 | -1.4 % | $ 283 M | USA |
 |
Cidara Therapeutics
CDTX
|
-0.873 | - | - | $ 1.41 B | USA |